MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-05-2025
Penumbra Accounts Receivables 2011-2026 | PEN
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Penumbra
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 168 M | 202 M | 203 M | 134 M | 115 M | 106 M | 81.9 M | 58 M | 43.3 M | 29.4 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 203 M | 29.4 M | 114 M |
Quarterly Accounts Receivables Penumbra
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 183 M | 176 M | 168 M | 176 M | 201 M | 192 M | 207 M | 209 M | 207 M | 203 M | 189 M | - | 143 M | 134 M | 120 M | - | 126 M | 115 M | 115 M | 115 M | 115 M | 106 M | 106 M | 106 M | 106 M | 81.9 M | 80.4 M | 74.1 M | 65.1 M | 58 M | 58 M | 58 M | 58 M | 43.3 M | 43.3 M | 43.3 M | 43.3 M | 29.4 M | 29.4 M | 29.4 M | 29.4 M | 18.9 M | 18.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 209 M | 18.9 M | 107 M |
Accounts Receivables of other stocks in the Medical devices industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AxoGen
AXGN
|
24.1 M | $ 33.22 | 1.87 % | $ 1.47 B |  USA |
 |
Allied Healthcare Products
AHPI
|
2.37 M | - | 3.58 % | $ 2.21 M | USA |
 |
Apollo Endosurgery
APEN
|
15 M | - | - | $ 475 M | USA |
 |
Axonics Modulation Technologies
AXNX
|
44.8 M | - | - | $ 3.31 B | USA |
 |
Acutus Medical
AFIB
|
11.4 M | - | -26.83 % | $ 2.62 M | USA |
 |
Aziyo Biologics
AZYO
|
3.26 M | - | 1.37 % | $ 20.5 M | USA |
 |
Cognyte Software Ltd.
CGNT
|
175 M | $ 7.01 | 2.04 % | $ 503 M |  Israel |
 |
Apyx Medical Corporation
APYX
|
14 M | $ 3.76 | -1.7 % | $ 130 M | USA |
 |
Alphatec Holdings
ATEC
|
83 M | $ 13.29 | 1.41 % | $ 1.9 B | USA |
 |
BIOLASE
BIOL
|
5.48 M | - | -13.19 % | $ 166 K | USA |
 |
Bio-Rad Laboratories
BIO
|
452 M | $ 255.19 | -12.51 % | $ 7.2 B | USA |
 |
Conformis
CFMS
|
9.77 M | - | - | $ 16.4 M | USA |
 |
Bruker Corporation
BRKR
|
566 M | $ 36.35 | -3.09 % | $ 5.42 K | USA |
 |
BioSig Technologies
BSGM
|
109 K | - | 37.08 % | $ 85.7 M | USA |
 |
CONMED Corporation
CNMD
|
238 M | $ 41.59 | -0.28 % | $ 1.28 B | USA |
 |
Abbott Laboratories
ABT
|
6.92 B | $ 112.22 | 0.66 % | $ 195 B | USA |
 |
Cardiovascular Systems
CSII
|
39.7 M | - | 0.15 % | $ 844 M | USA |
 |
EDAP TMS S.A.
EDAP
|
18.6 M | $ 4.8 | 0.63 % | $ 179 M |  France |
 |
Delcath Systems
DCTH
|
10.9 M | $ 9.25 | 1.43 % | $ 264 M | USA |
 |
Cutera
CUTR
|
43.1 M | - | -10.19 % | $ 1.99 M | USA |
 |
ClearPoint Neuro
CLPT
|
4.71 M | $ 13.44 | 3.07 % | $ 363 M | USA |
 |
Electromed
ELMD
|
24.7 M | $ 24.2 | 3.82 % | $ 205 M | USA |
 |
Dynatronics Corporation
DYNT
|
2.8 M | - | 14.99 % | $ 929 K | USA |
 |
Eargo
EAR
|
1.91 M | - | - | $ 10.2 M | USA |
 |
Inogen
INGN
|
29.6 M | $ 5.71 | -1.38 % | $ 135 M | USA |
 |
InMode Ltd.
INMD
|
10.5 M | $ 14.36 | 0.38 % | $ 1.14 B | Israel |
 |
IRadimed Corporation
IRMD
|
10.6 M | $ 99.81 | -0.03 % | $ 1.26 B | USA |
 |
GBS
GBS
|
595 K | - | -0.57 % | $ 7.12 M | USA |
 |
Integer Holdings Corporation
ITGR
|
245 M | $ 85.46 | 0.23 % | $ 2.87 B | USA |
 |
Second Sight Medical Products
EYES
|
455 K | - | -0.97 % | $ 54.4 M | USA |
 |
Avinger
AVGR
|
1.01 M | - | -20.74 % | $ 369 K | USA |
 |
Pulmonx Corporation
LUNG
|
13.1 M | $ 1.47 | 3.17 % | $ 57.5 M | USA |
 |
Globus Medical
GMED
|
558 M | $ 87.89 | 0.76 % | $ 11.9 B | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
272 M | $ 11.29 | 4.46 % | $ 869 M | USA |
 |
Myomo
MYO
|
1.9 M | $ 0.82 | 0.41 % | $ 5.78 M | USA |
 |
Establishment Labs Holdings
ESTA
|
65 M | $ 75.22 | 2.28 % | $ 2.12 B |  Costa-rica |